Physician profile
Robert G Shellman
NPI 1659339927
$16,158.31
in general payments reported to CMS, 2019-2025
48 companies · $2,433 in 2025
The $2,433 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,390 · 2020: $1,392 · 2021: $2,071 · 2022: $2,291 · 2023: $2,580 · 2024: $3,002 · 2025: $2,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,804 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,804.04 |
| Education | $211.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,637.74 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,381.15 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $871.52 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $806.82 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Harmony Biosciences LLC | $793.12 | 2020-2025 | Wakix |
| Genzyme Corporation | $779.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $730.68 | 2020-2025 | Glassia |
| Grifols USA, LLC | $682.60 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $623.24 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $594.57 | 2019-2025 | |
| Insmed, INC. | $486.18 | 2019-2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $339.00 | 2023-2025 | Sunosi |
| Amgen INC. | $295.11 | 2022-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $279.79 | 2019-2021 | |
| United Therapeutics Corporation | $249.03 | 2020-2024 | Tyvaso |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $240.83 | 2021-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $233.76 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $206.91 | 2019-2024 | Xarelto |
| Verona Pharma, INC. | $186.19 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $184.85 | 2022-2024 | Acthar |
| Actelion Pharmaceuticals US, INC. | $145.94 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Vifor Pharma, INC. | $133.65 | 2019-2025 | Zemaira |
| Genentech USA, INC. | $122.36 | 2019-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $118.81 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $94.42 | 2019-2022 | |
| Philips North America LLC | $73.47 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $71.01 | 2024 | Lumryz |
| Advanced Respiratory, INC | $70.27 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $67.19 | 2020-2025 | Winrevair |
| Ucb, INC. | $60.43 | 2019 | |
| Viatris Specialty LLC | $57.29 | 2025 | Yupelri |
| Gilead Sciences, INC. | $56.77 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $56.22 | 2019-2024 | Eliquis |
| Pulmonx Corporation | $48.14 | 2019-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Covis Pharma Gmbh | $47.74 | 2022-2023 | |
| Itamar Medical INC | $45.83 | 2025 | Watchpatone |
| Mayne Pharma Commercial LLC | $45.12 | 2019-2021 | |
| Pfizer INC. | $41.02 | 2022-2025 | |
| Inspire Medical Systems, INC. | $35.82 | 2024-2025 | Inspire |
| Medtronic, INC. | $29.10 | 2025 | Venaseal |
| Astellas Pharma US INC | $19.76 | 2023 | Cresemba |
| Mallinckrodt Enterprises LLC | $19.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.60 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $17.73 | 2024 | |
| Resmed Corp | $17.32 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.05 | 2023 | Arcalyst |
| Optinose US, INC. | $14.89 | 2021 | |
| Arbor Pharmaceuticals, INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.